Alcon Inc. (ETR:2U3)
Market Cap | 37.08B |
Revenue (ttm) | 9.18B |
Net Income (ttm) | 1.04B |
Shares Out | n/a |
EPS (ttm) | 2.08 |
PE Ratio | 35.78 |
Forward PE | 26.69 |
Dividend | 0.30 (0.41%) |
Ex-Dividend Date | May 13, 2025 |
Volume | n/a |
Average Volume | 5 |
Open | 74.68 |
Previous Close | 73.64 |
Day's Range | 74.68 - 74.68 |
52-Week Range | 52.91 - 86.62 |
Beta | n/a |
RSI | 49.18 |
Earnings Date | Aug 20, 2025 |
About Alcon
Alcon Inc. researches, develops, manufactures, distributes, and sells eye care products worldwide. It operates through two segments, Surgical and Vision Care. The company offers equipment, instrumentation and diagnostics, intraocular lenses (IOLs), and other implantables; and consumables, including viscoelastics, surgical solutions, incisional instruments, surgical custom packs, and other products for surgical procedures. Its cataract products include Centurion vision system, LenSx laser system, Verion reference unit and Verion digital marker, ... [Read more]
Financial Performance
In 2024, Alcon's revenue was $9.91 billion, an increase of 4.82% compared to the previous year's $9.46 billion. Earnings were $1.02 billion, an increase of 4.52%.
Financial numbers in USD Financial StatementsNews
Key deals this week: Walt Disney, Harrison Global, Alcon, Steelcase, Joby Aviation and more
STAAR Surgical's largest holder demands books, records on Alcon deal

STAAR SURGICAL INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of STAAR Surgical Company - STAA
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of STAAR Surgical Company (NasdaqGM: STAA) to Alc...

STAAR SURGICAL INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of STAAR Surgical Company - STAA
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of STAAR...

Johnson Fistel Investigates Fairness of Proposed Sale of STAAR Surgical
SAN DIEGO, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Shareholder rights law firm Johnson Fistel, PLLP has launched an investigation into whether the board members of STAAR Surgical Company (NASDAQ: STAA) brea...

STAA Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of STAAR Surgical Company Is Fair to Shareholders
Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of STAAR Surgical Company (NASDAQ: STAA) to Alcon for $28.00 per share in cash is fair to STAAR shareholders. Halper Sa...

Why Palantir Technologies Shares Are Trading Higher By Over 5%; Here Are 20 Stocks Moving Premarket
Shares of Palantir Technologies Inc. (NASDAQ: PLTR) rose sharply in pre-market trading after the company reported better-than-expected financial results for the second quarter and raised its full-yea...
Alcon to buy STAAR Surgical for $28 per share
Alcon to acquire STAAR Surgical for $1.5B, expanding offerings in refractive surgery. Deal expected to close in 6-12 months.

Alcon Agrees to Acquire STAAR Surgical
Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, and STAAR Surgical Company (NASDAQ: STAA), the manufacturer of the Implantable Collamer Lens (ICL), to...

Alcon Agrees to Acquire STAAR Surgical
GENEVA & LAKE FOREST, Calif.--(BUSINESS WIRE)--Alcon Agrees to Acquire STAAR Surgical.
Lensar And Alcon: Assessing Potential Outcomes

Alcon’s Latest Breakthrough Surgical Technology, Unity VCS, receives Health Canada approval
Alcon, the global leader in eye care dedicated to helping people see brilliantly, today announced that UNITY Vitreoretinal Cataract System (VCS) has received Health Canada approval. This innovation is...

Alcon's Latest Breakthrough Surgical Technology, Unity VCS, receives Health Canada approval
TORONTO--(BUSINESS WIRE)-- #AlconCanada--Alcon, the global leader in eye care dedicated to helping people see brilliantly, today announced that UNITY® Vitreoretinal Cataract System (VCS) has received ...
Alcon to acquire LumiThera for dry AMD treatment device

Alcon to Acquire LumiThera and Its Photobiomodulation Device for the Treatment of Early and Intermediate Dry Age-Related Macular Degeneration (AMD)
Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced its intention to acquire LumiThera, Inc., a leader in light-based innovations for opht...

Alcon Canada Earns Global Recognition as a Top Employer
TORONTO--(BUSINESS WIRE)-- #AlconCanada--Alcon, the global leader in eye care dedicated to helping people see brilliantly, today announced that Alcon Canada has been certified as a Top Employer in Can...

Alcon Canada Earns Global Recognition as a Top Employer
Alcon, the global leader in eye care dedicated to helping people see brilliantly, today announced that Alcon Canada has been certified as a Top Employer in Canada by the Top Employers Institute, a rec...

Gordon Schanzlin New Vision Institute Becomes First U.S. Clinic to Use Alcon's Breakthrough Unity Phaco System
Dr. Echegoyen Participated in Clinical Trials for the First Major Phacoemulsification Advancement in Over 15 Years Dr. Echegoyen Participated in Clinical Trials for the First Major Phacoemulsification...

Alcon Introduces Clareon PanOptix Pro in Canada, Delivering the Lowest Light Scatter of any Trifocal IOL
Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced the approval of Clareon PanOptix Pro intraocular lens (IOL) for cataract patients in C...

Alcon Introduces Clareon PanOptix Pro in Canada, Delivering the Lowest Light Scatter of any Trifocal IOL
TORONTO--(BUSINESS WIRE)-- #AlconCanada--Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced the approval of Clareon® PanOptix® Pro intrao...
Alcon's Tryptyr Adds Growth, But Valuation Keeps Shares On 'Hold'

LENSAR INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of LENSAR, Inc. - LNSR
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of LENSAR, Inc. (NasdaqCM: LNSR) to Alcon Inc. (N...

LENSAR INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of LENSAR, Inc. - LNSR
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of LENSA...

Alcon Secures First FDA Approval Since Novartis Spin-Off In 2019
The U.S. Food and Drug Administration (FDA) on Wednesday approved Alcon Plc’s (NYSE: ALC) Tryptyr (acoltremon ophthalmic solution) 0.003%, formerly known as AR-15512, for signs and symptoms of Dry Ey...

US FDA approves Alcon's new dry-eye drug
Eye-care drugmaker Alcon said on Wednesday that the U.S. Food and Drug Administration has approved its treatment for dry eye disease (DED).